Our integrated genomic approach is the first that specifically isolates the tumor-suppressive gene expression responses to TGF-β from the tumor-promoting or tumor-unrelated responses, and our results suggest that TGF-β-driven tumor-suppressive responses contribute importantly to good clinical outcome in a subset of patients with ER+ breast cancer. This evidence concerns the gene TGFB1 and breast carcinoma.